Nordic Pharma's Innovative Lacrifill Gel Featured in DEWS III Report Recognizing Advances in Dry Eye Management

Nordic Pharma's Lacrifill Canalicular Gel Gains Recognition in DEWS III Report

Nordic Pharma, Inc., a prominent arm of Nordic Group B.V., has announced the inclusion of its innovative Lacrifill Canalicular Gel in the newly published DEWS III report from the Tear Film and Ocular Surface Society (TFOS), featured in the June 2025 issue of the American Journal of Ophthalmology. This report represents a significant effort in addressing the challenges faced by physicians when managing dry eye disease (DED) and highlights new, effective therapies.

Lacrifill Canalicular Gel is a novel formulation designed specifically to alleviate symptoms of dry eye by utilizing advanced crosslinked hyaluronic acid (HA) technology. Within the DEWS III report, two pivotal studies cited demonstrate the impressive benefits of this treatment. One study reports marked improvements in corneal staining, Schirmer test results, and patient symptoms after just three months of administration.

In a comparative analysis, Lacrifill was pitted against an existing hydrogel canalicular plug. The findings revealed that Lacrifill not only meets safety standards but also offers significant and sustained enhancements in both the signs and symptoms of dry eye disease, persisting through a six-month follow-up period. Such encouraging results signify a paradigm shift in the management of DED, emphasizing the potential of Lacrifill as a front-line treatment option.

Adding further credence to the data, a poster presentation at the Women in Ophthalmology (WIO) Summer Symposium from August 7-10 will delve deeper into the latest research surrounding Lacrifill. This poster, authored by Dr. Monica Patel and her collaborators, assessed 117 patients one month post-application of Lacrifill, revealing that over 66% of participants self-reported symptom relief of at least 50%, with some patients experiencing symptom relief upwards of 90% to 100% in burning and sandy sensations.

Dr. Patel, the Medical Director of Clear Vision Ophthalmology, asserts that these findings underscore the efficacy of Lacrifill across various patient demographics, including those who might have concurrent conditions, such as diabetes or thyroid disease complicated by glaucoma. She emphasized the reliability of self-reporting methods combined with Ocular Surface Disease Index (OSDI) scores as valuable assessment tools for evaluating the effectiveness of new treatments.

The positive feedback from practitioners and patients alike reflects the real-world applicability of Lacrifill. Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., concurred, stating that the study's outcomes affirm Lacrifill's role as a significant player in alleviating dry eye symptoms effectively.

Additionally, two substantial case studies published recently showcase the clinical effectiveness of Lacrifill. One detailed the experience of a patient who encountered visual disturbances post-refractive cataract surgery, which persisted despite various other treatments. The administration of Lacrifill markedly improved the tear film and vision quality, demonstrating its potential as a retrial therapy in complex cases.

Another case highlighted the success of Lacrifill in a patient grappling with Demodex blepharitis alongside exacerbated dry eye symptoms. This anecdote, published in Modern Optometry, showcased significant recoveries, such as advancements in pain relief scores and overall ocular health restoration.

In summary, Nordic Pharma's Lacrifill Canalicular Gel is not only at the forefront of novel therapeutics for dry eye management but is also gaining broad recognition within the medical community. As further research continues to unveil the advantages and versatile applications of this treatment, clinicians might have a robust solution to offer their patients suffering from DED.